Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know.
Key Points
The disposition involved 15,311 shares valued at about $380,000 based on a weighted average price of $24.80 per share.
The transaction reduced the insider's direct holdings by 3% following the underlying vesting event.
This activity was entirely non-discretionary, executed solely to satisfy tax withholding obligations associated with the settlement of restricted stock units.
- 10 stocks we like better than Doximity ›
Matthew Sonefeldt, the chief financial officer of Doximity, Inc. (NYSE:DOCS), reported a non-discretionary disposition of 15,311 shares of Class A Common Stock on August 15, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 15,311 |
| Transaction value | $380,000 |
| Post-transaction shares (directly held) | 486,238 |
| Post-transaction value | $12.1 million |
Transaction value based on SEC Form 4 weighted average sale price ($24.80).
Key questions
- Does this transaction reflect a shift in the executive's outlook on the firm?
The disposition was a non-discretionary event triggered by tax liabilities linked to equity compensation vesting. Because the shares were withheld by the company to cover these obligations rather than sold in an open-market discretionary trade, the move does not provide a signal regarding the CFO's view on the stock's valuation. - What is the scale of the remaining incentive alignment?
Sonefeldt maintains a significant equity interest in the company, holding 486,238 shares directly. This position represents a substantial capital commitment of $12.1 million based on the market close price of $24.80 on August 14. - What are the core fundamentals of the business at the time of this filing?
The company operates a digital platform for healthcare practitioners, generating trailing 12-month revenue of $655.6 million and net income of $167.0 million. Its primary client base includes pharmaceutical companies and healthcare organizations that utilize the platform for peer networking and remote consultations.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-14) | $24.80 |
| Market Capitalization | $4.6 billion |
| Revenue (TTM) | $655.6 million |
| Net Income (TTM) | $167.0 million |
Company Snapshot
- Doximity operates a cloud-hosted digital platform that provides healthcare practitioners with specialized tools for peer connectivity, patient care coordination, remote consultations, medical research access, and professional development.
- The company generates revenue through subscription-based services and licensing arrangements with pharmaceutical companies and healthcare organizations that utilize the platform to engage with medical professionals.
- The primary customer base consists of pharmaceutical companies seeking to reach physicians and healthcare organizations seeking to optimize clinical workflows and practitioner engagement across the United States healthcare system.
Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established relationships with pharmaceutical and healthcare organization customers.
What this transaction means for investors
Sonefeldt has been Doximity's CFO for roughly one quarter as of lastweek, which makes this the first tranche of a new hire's equity vesting and the tax bill that comes with it. Three other insiders had the same thing happen the same day, so the filing itself isn't what's worth lingering on.
The more useful thing about Sonefeldt is what he keeps talking about. On the August 6 call he returned again and again to LinkedIn, where he worked before, and to how its ad business only got enormous after buying shifted to auctions over many years. He was careful to say Doximity isn't unveiling that this year. Instead, this year is a lot less tidy for Doximity. Revenue rose 7% to $156.6 million, but the September quarter is guided to $170 million to $171 million, roughly 1% growth at the midpoint. Sonefeldt said on the same call that "the overall pharma spending environment remains tight," which sits awkwardly next to a raised full-year outlook. AI compute costs pulled gross margin to 87.5% from 91.2%, and adjusted EBITDA slipped 6% to $74.8 million while the company spent $91.6 million buying back stock. His own explanation for the weak growth is timing. The fiscal third quarter, when the AI search revenue lands, as the firm noted on the earnings call, is where that gets tested.
Should you buy stock in Doximity right now?
Before you buy stock in Doximity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Doximity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 18, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.
Recommended Articles
